Association between long-term exposure to metformin (≥5 years) and risk of myeloproliferative neoplasm according to subgroups
| Subgroup . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|
| Age group | ||
| <60 y | 0.96 (0.32-2.81) | 0.47 (0.15-1.50) |
| 60-75 y | 0.59 (0.38-0.91) | 0.45 (0.28-0.71) |
| >75 y | 0.50 (0.30-0.85) | 0.46 (0.27-0.78) |
| Sex | ||
| Male | 0.46 (0.29-0.74) | 0.37 (0.23-0.60) |
| Female | 0.71 (0.46-1.09) | 0.56 (0.36-0.89) |
| Disease subtype | ||
| PV | 0.57 (0.34-0.97) | 0.45 (0.26-0.77) |
| ET | 0.39 (0.20-0.78) | 0.33 (0.16-0.67) |
| MF | 0.89 (0.46-1.72) | 0.65 (0.32-1.33) |
| MPN-U | 0.59 (0.27-1.30) | 0.46 (0.20-1.06) |
| Molecular subtype | ||
| JAK2-V617F-mutated | 0.61 (0.43-0.87) | 0.47 (0.32-0.68) |
| CALR-mutated | 0.57 (0.13-2.48) | 0.53 (0.11-2.50) |
| No AD | 0.59 (0.43-0.83) | 0.46 (0.32-0.64) |
| Subgroup . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|
| Age group | ||
| <60 y | 0.96 (0.32-2.81) | 0.47 (0.15-1.50) |
| 60-75 y | 0.59 (0.38-0.91) | 0.45 (0.28-0.71) |
| >75 y | 0.50 (0.30-0.85) | 0.46 (0.27-0.78) |
| Sex | ||
| Male | 0.46 (0.29-0.74) | 0.37 (0.23-0.60) |
| Female | 0.71 (0.46-1.09) | 0.56 (0.36-0.89) |
| Disease subtype | ||
| PV | 0.57 (0.34-0.97) | 0.45 (0.26-0.77) |
| ET | 0.39 (0.20-0.78) | 0.33 (0.16-0.67) |
| MF | 0.89 (0.46-1.72) | 0.65 (0.32-1.33) |
| MPN-U | 0.59 (0.27-1.30) | 0.46 (0.20-1.06) |
| Molecular subtype | ||
| JAK2-V617F-mutated | 0.61 (0.43-0.87) | 0.47 (0.32-0.68) |
| CALR-mutated | 0.57 (0.13-2.48) | 0.53 (0.11-2.50) |
| No AD | 0.59 (0.43-0.83) | 0.46 (0.32-0.64) |
NSAIDs, nonsteroidal anti-inflammatory drugs.
Adjusted for age, sex, and calendar time.
Adjusted for in addition to the following: (1) education level (primary school; high school; short/middle long education; long education); (2) CCI (0; 1; ≥2); (3) previous use of aspirin or other NSAIDs, alendronate, immunosuppressants, or statins; and (4) history of alcohol-related diagnoses, overweight and obesity-related diagnoses, chronic obstructive pulmonary disease, and autoimmune disease